LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Hosted on MSN5d
Eli Lilly's Q4 2024 Earnings: What to Expect
Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...
Eli Lilly Q4 miss brings buying opportunity, says JPMorgan
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
bovnews3d
Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...
Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25
Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...
Leerink Partnrs Has Bearish Outlook for LLY FY2024 Earnings
Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Insider Monkey4d
Why Eli Lilly (LLY) Stock Is Declining Today
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...